SCHEMBL4664339

SCHEMBL4664339

CN1CCC(CCn2ccc3cc(-c4cc(Nc5ccc(NS(=O)(=O)c6ccc(F)cc6)cc5)ncn4)ccc32)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 3/20 0.43
ABL1 P00519 3/20 0.41
BCR P11274 3/20 0.41
GSK3B P49841 1/20 0.40
HSD17B10 Q99714 2/20 0.39
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
GLA P06280 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4663912 0.93 GSK3B (0.42) ABL1BCRGSK3BALDH1A1KMT2A
Formic Acid SCHEMBL4665686 0.91 ABL1 (0.40) EGFRABL1BCRGSK3BHSD17B10
SCHEMBL4666185 0.90 LMNA (0.43) ABL1BCRLMNAALDH1A1TP53
Formic Acid SCHEMBL4666026 0.89 GSK3B (0.42) ABL1BCRGSK3BLMNAALDH1A1
Formic Acid SCHEMBL4663801 0.88 GSK3B (0.41) EGFRABL1BCRGSK3BMEN1
Formic Acid SCHEMBL4666035 0.88 PRF1 (0.41) ABL1BCRTP53
SCHEMBL4664323 0.87 PRF1 (0.37) ABL1BCRGSK3BCYP3A4KIT
Formic Acid SCHEMBL4664270 0.86 ABL1 (0.37) ABL1BCRUSP2CYP1A2CYP3A4
Formic Acid SCHEMBL4663822 0.85 SGK1 (0.39) ABL1BCR
Formic Acid SCHEMBL4664235 0.82 GSK3B (0.40) EGFRABL1BCRGSK3BMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 EGFR 279/4885ABL1 24/4885BCR 402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.